For instance, Venetoclax (a BCL-2–specific inhibitor) and Navitoclax (inhibitors of BCL-2, BCL-xL, and BCL-W) have shown promise in the treatment of leukemia and lymphoma (26, 27). Here, BCL2 is linked to lymphoma.